Mr. D'Amelio provides unparalleled institutional knowledge of Zoetis, having been instrumental in conceptualizing and establishing the Company as a standalone entity from Pfizer. He brings exceptional financial acumen and extensive M&A expertise from his role as Executive Vice President and Chief Financial Officer of Pfizer, having led numerous acquisitions, partnerships and divestitures, including the transformative divestiture of the animal health business that created Zoetis. His pragmatism and deep operational experience overseeing global supply chains, information technology and major business transformations, combined with his extensive public company board service, contributes an invaluable perspective to the Board.
As the former Executive Vice President and Chief Financial Officer of Pfizer Inc., as well as several other senior leadership roles, was responsible for Business Operations and Global Supply divisions, and finance, operations and strategic initiatives.
Led acquisitions, partnerships and divestitures valued at nearly $200 billion during tenure at Pfizer, including transformative transactions such as the acquisition of Wyeth and the divestiture of the animal health business that created Zoetis, bringing unparalleled M&A expertise and a deep understanding of the company’s history and strategic value proposition.
Extensive operational expertise overseeing global supply chains, information technology functions and major business transformations, including large-scale technology implementations of enterprise risk management programs, with proven ability to provide pragmatic guidance on appropriate budgeting and transformative impact of major projects.
Significant public company board experience, currently serving on the boards of directors of Humana Inc. (since 2003), Hewlett Packard Enterprise (since 2023) and Viatris Inc. (since May 2025), with previous service on the boards of Catalent Inc. and the National Advisory Board of JPMorgan Chase & Co., bringing extensive governance perspective.
What is Frank A. Damelio's net worth?
The estimated net worth of Frank A. Damelio is at least $1.59 million as of May 13th, 2026. Damelio owns 21,458 shares of Zoetis stock worth more than $1,590,188 as of May 15th. This net worth approximation does not reflect any other assets that Damelio may own. Learn More about Frank A. Damelio's net worth.
How do I contact Frank A. Damelio?
Has Frank A. Damelio been buying or selling shares of Zoetis?
During the last quarter, Frank A. Damelio has bought $501,343.50 in Zoetis stock. Most recently, on Wednesday, May 13th, Frank A. Damelio bought 6,650 shares of Zoetis stock. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director now directly owns 21,458 shares of the company's stock, valued at $1,617,718.62. Learn More on Frank A. Damelio's trading history.
Who are Zoetis' active insiders?
Zoetis' insider roster includes Juan Alaix (Director), Paul Bisaro (Director), Heidi Chen (EVP), Frank Damelio (Director), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Michael Mccallister (Director), Gregory Norden (Director), Kristin Peck (CEO & Director), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?
In the last twelve months, Zoetis insiders bought shares 3 times. They purchased a total of 11,650 shares worth more than $886,383.50. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 652 shares worth more than $110,840.00. The most recent insider tranaction occured on May, 13th when Director Frank A Damelio bought 6,650 shares worth more than $501,343.50. Insiders at Zoetis own 0.2% of the company.
Learn More about insider trades at Zoetis. Information on this page was last updated on 5/13/2026.
